Featured image for “Tinnitus and Musicians: When a Highly Trained Ear Meets a Benign Signal”
Nov. 18, 2026

Tinnitus and Musicians: When a Highly Trained Ear Meets a Benign Signal

HHTM
by Dr. Jennifer J. Gans For musicians, the ear is not just a sense organ—it is the foundation of identity, craft, and livelihood. Just as an Olympic athlete depends on the integrity of their body, musicians depend on the precision of their hearing. A small change in pitch, tone, or timing is not a minor detail—it is the work itself.
Featured image for “Skylark Bio Receives Green Light to Expand Pediatric Hearing Loss Gene Therapy Trial”
Nov. 18, 2026

Skylark Bio Receives Green Light to Expand Pediatric Hearing Loss Gene Therapy Trial

HHTM
CAMBRIDGE, MASSACHUSETTS — Skylark Bio announced that an independent Data Safety Monitoring Board (DSMB) has unanimously recommended advancing its investigational gene therapy, SKY-GJB2, into the next stage of the SONIX Phase 1/2 clinical trial. The decision follows a review of safety data from the first four children treated in the study, allowing researchers to begin enrolling younger participants. The next cohort
Featured image for “WSA Reports 2% Annual Growth, Highlights New Signia and Widex Hearing Aids”
Nov. 18, 2026

WSA Reports 2% Annual Growth, Highlights New Signia and Widex Hearing Aids

HHTM
LYNGE, DENMARK — WS Audiology (WSA), the parent company of hearing aid brands Signia and Widex, reported 2% organic revenue growth for its 2025/26 financial year, with improved profitability despite slower sales through its wholesale hearing aid business. The company generated €2.54 billion (~$2.79 billion) in revenue during the 12 months ending September 30, 2026. Although underlying sales increased 2% after
Featured image for “Upcoming Neurotone AI Webinars Explore Tinnitus, Auditory Training, and CE Opportunities”
Nov. 18, 2026

Upcoming Neurotone AI Webinars Explore Tinnitus, Auditory Training, and CE Opportunities

HHTM
Neurotone AI is offering a series of educational webinars for hearing care professionals in the United States and Canada, focusing on patient counseling, tinnitus outcomes, and strategies for incorporating auditory training into clinical practice. The sessions, led by Dr. Miles Aron, are designed primarily for hearing care providers working in private practice. Topics include supporting patients who are hesitant to
Featured image for “ShokzHear OpenHear BM420 Bone Conduction Hearing Aid Earns CES 2027 Innovation Award”
Nov. 17, 2026

ShokzHear OpenHear BM420 Bone Conduction Hearing Aid Earns CES 2027 Innovation Award

HHTM
AUSTIN, TEXAS — Shokz has announced that its OpenHear BM420 bone conduction hearing aid has been named a CES 2027 Innovation Awards Honoree in the Accessibility & Longevity category. Developed by ShokzHear, an affiliated professional hearing-care company of Shokz, the device represents an expansion of the company’s established open-ear audio technology into professionally fitted hearing solutions. The OpenHear BM420 is
Featured image for “Sonova Raises Full-Year Outlook Following Strong Growth in Hearing Aid Sales”
Nov. 17, 2026

Sonova Raises Full-Year Outlook Following Strong Growth in Hearing Aid Sales

HHTM
STÄFA, SWITZERLAND — Sonova reported strong growth in hearing aid sales during the first half of its 2026/27 financial year, supported by demand for newer Phonak products, expanded relationships with major customers, and increased deliveries to the U.S. Department of Veterans Affairs (VA). The Swiss hearing technology company, whose brands include Phonak, Unitron, and Advanced Bionics, reported total sales of CHF
Featured image for “Cilcare Expands Hearing Loss Drug Pipeline with Two New Sanofi Agreements”
Nov. 16, 2026

Cilcare Expands Hearing Loss Drug Pipeline with Two New Sanofi Agreements

HHTM
MONTPELLIER, FRANCE — Hearing therapeutics company Cilcare has announced two exclusive licensing agreements with pharmaceutical company Sanofi covering investigational drug candidates targeting different biological mechanisms associated with hearing loss. The agreements cover CIL005, a program targeting inflammation in the cochlea, and CIL006, which targets oxidative stress, with an initial focus on a rare hearing disorder. Both programs will undergo further
Featured image for “Neurotone AI’s Lace Pro Auditory Training Now Integrated with Auditdata Manage”
Nov. 16, 2026

Neurotone AI’s Lace Pro Auditory Training Now Integrated with Auditdata Manage

HHTM
Auditdata has announced a partnership with Neurotone AI to integrate the Lace Pro auditory training program into its Manage practice management system, allowing hearing care professionals to incorporate auditory training more easily into routine clinical workflows. The integration connects Neurotone AI’s digital auditory training platform with Auditdata’s audiology-specific practice management software, enabling clinics to provision Lace Pro licenses directly through
Featured image for “Widex Allure AI RIC Now Available Nationwide Through HearUSA”
Nov. 16, 2026

Widex Allure AI RIC Now Available Nationwide Through HearUSA

HHTM
TAMPA, FLORIDA — HearUSA has announced the nationwide availability of the Widex Allure AI RIC hearing aid across its hearing care network, expanding patient access to technology that combines Widex’s natural sound processing with user-activated artificial intelligence (AI) support for challenging listening environments. Developed by Widex, part of WS Audiology, the Allure AI RIC is designed to help wearers maintain
Featured image for “New NAL-NL3 Research Offers Hearing Aid Fitting Guidance for Adults with Minimal Hearing Loss”
Nov. 15, 2026

New NAL-NL3 Research Offers Hearing Aid Fitting Guidance for Adults with Minimal Hearing Loss

HHTM
For many audiologists, it is a familiar clinical scenario: a patient reports difficulty following conversations in restaurants, group settings, or other noisy environments, yet their hearing test shows normal or near-normal results. While these communication difficulties may be significant, conventional hearing aid fitting approaches have offered limited guidance on whether amplification could help or how much gain should be prescribed.